292

IMSUT Hospital

IMSUT CORD

臍帯血・臍帯バンク
Clinical Professor Tokiko Nagamura-Inoue, M.D., Ph.D.

病院教授

博士（医学）

長村登紀子

Recently, umbilical cord blood (CB) has received attention as the optimum
allogeneic source for immunotherapies. The umbilical cord tissue (UC) also has
been rapidly utilized as an abundant source of mesenchymal stromal cells (MSCs),
which migrate toward inflamed or damaged tissue to reduce inflammation andsupport tissue repair. Both CB and UC can be provided as “off-the-shelf” cellproducts for immunotherapies and regenerative medicine. IMSUT CORD is the CBand UC-derived cell bank established in IMSUT hospital in 2016. The aim of IMSUTCORD is to collect, process /culture, cryopreserve, stock, and release CB- and UCderived cells—including mesenchymal stromal cells (MSCs)—for clinical andresearch use. We have released CB and UC-derived MSCs to researchers undermaterial transfer agreements to expedite translational studies. We have supplied
UC-MSC products for clinical trials for severe acute graft-versus-host disease(GVHD; 2018– 2020), COVID-19-related ARDS (2020–2022), cerebral palsy (PVL;2021–2023), and noninfectious pulmonary complication after allogeneic
hematopoietic stem cell transplantation NIPC; 2022–2023). Our main processing
facility has been moved from IMSUT cell resource center to new IMSUT-HLC cellprocessing facility since 2021.

1.  Establishing a stable perinatal appendage–derived cell supply system as the source of allogeneic somatic stem cells for research andclinical use
Nagamura-Inoue T, Takahashi A, Hori A, Miharu Y,
Sakai T, Shibuya Y, Nagaya N, Ogami K, Mukai T,Nagamura F
Human umbilical cord blood (CB) and umbilicalcord tissue (UC) are attractive sources of somatic stem
cells for gene and cell therapies. CB and UC can beobtained noninvasively from donors. CB, a known
source of hematopoietic stem cells for transplantation, has attracted attention as a new source of immune cells, including universal chimeric antigen receptor-T cell therapy (CAR-T) and, more recently,
universal CAR-natural killer cells. UC-derived mes-enchymal stromal cells (UC-MSCs) have a higher proliferation potency than those derived from adult tissues and can be used anon-HLA restrictively. We
have established a CB/UC bank at the IMSUT hospital(IMSUT CORD) to collect CB and UC tissue after informed consent from the mothers in collaboration
with the obstetricians. After receiving them, we stock
the UC-tissue, and to manufacture master cells andproduct cells for research and clinical use.
To maintain quality control, we have introduced
the ISO 9001:2015 quality management standards inIMSUT CORD since 2018. We have transferred themanufacturing and testing technologies to the clientcompanies, where they apply our techniques andstandards in their clinical trials including therapies
for acute GVHD, cerebral palsy, and COVID-19 related acute respiratory distress syndrome (ARDS). TheIMSUT CORD mission is to supply domestic UC-293
MSCs and CB as a source of allogeneic somatic stem
cells in research and clinical use. We have suppliedclinical-grade UC-MSC products for clinical trials including severe acute graft-versus-host disease(GVHD; 2018-2020), COVID-19-related ARDS (20202022), cerebral palsy (PVL)(2021-2023), and non-infectious pulmonary disease after allogeneic hematopoietic stem cell transplantation NIPS; 2022-2023), after
approval by the review board of IMSUT CORD andPMDA. We are currently preparing for a clinical trialfor treating peripheral nerve injury using allograft bi-o3D conduit made with UC-MSC products with Kyoto University (AMED project 2022-). Since 2021, ourmain manufacturing location has been moved fromthe IMSUT-Cell Resource Center (IMSUT-CRC) to a
new facility, the IMSUT-HLC Cell Processing Facility(IMSUT-HLC CPF), where the manufacturing license
was obtained in 2023.
Visit our website:
https://plaza.umin.ac.jp/imsutcord/Publications
1.		Nagamura-Inoue T, Nagamura F., Umbilical cord
blood and cord tissue banking as somatic stem cellresources to support medical cell modalities, Inflamm Regen. 2023 Dec 5;43(1):59.